Was Richard C. Breeden’s STERIS (STE) share sale part of a single trade?

The 1,481 STERIS shares were sold across multiple trades between $209.50 and $209.53 per share, producing a weighted average price of $209.51. Breeden has undertaken to provide detailed trade breakdowns to the SEC staff, the issuer, or any security holder upon request.

STERIS (STE) director Breeden exercises options and sells 1,481 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

STERIS plc director Richard C. Breeden reported option exercises and share sales. On 2026-06-02, he exercised options to acquire 3,781 Ordinary Shares at $71.40 per share and sold 1,481 Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share.

Following these transactions, Breeden directly owned 38,964 Ordinary Shares. A separate entry shows 27,242 Ordinary Shares held indirectly, with footnotes explaining these are owned through Breeden-affiliated investment entities and that he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership of 1,358 of those shares.

Insider Trade Summary

Net Seller: 1,481 shares ($310,284)

Net Sell 4 txns

Insider Breeden Richard C

Role null

Sold 1,481 shs ($310K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	3,781	$0.00	--
Exercise	Ordinary Shares	3,781	$71.40	$270K
Sale	Ordinary Shares	1,481	$209.51	$310K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct, null); Ordinary Shares — 40,445 shares (Direct, null); Ordinary Shares — 27,242 shares (Indirect, See Footnotes Below)

Footnotes (1)

Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund"). Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP. This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.

Key Figures

Shares sold: 1,481 shares Sale price (weighted average): $209.51 per share Options exercised: 3,781 shares +4 more

7 metrics

Shares sold 1,481 shares Open-market sale of Ordinary Shares on June 2, 2026

Sale price (weighted average) $209.51 per share Multiple trades between $209.50 and $209.53

Options exercised 3,781 shares Employee Stock Option exercise on June 2, 2026

Option exercise price $71.40 per share Conversion or exercise price for 3,781-share option

Direct holdings after transactions 38,964 shares Ordinary Shares owned directly following June 2, 2026 trades

Indirect holdings 27,242 shares Ordinary Shares held through Breeden-affiliated entities

Net buy/sell shares -1,481 shares Net effect of buy/sell activity in this Form 4

Key Terms

open-market sale, Employee Stock Option (right to buy), weighted average sale price, indirect beneficial owner, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Employee Stock Option (right to buy) financial

"security_title": "Employee Stock Option (right to buy)""

weighted average sale price financial

"Price reflects a weighted average sale price for multiple transactions"

indirect beneficial owner financial

"may be deemed to be the indirect beneficial owner of the ordinary shares"

Rule 16a-1(a)(2)(ii)(B) regulatory

"Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breeden Richard C

(Last)

(First)

(Middle)

C/O 70 SIR JOHN ROGERSON'S QUAY

(Street)

DUBLIN 2

D02 R296

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/02/2026		M		3,781	A	$71.4	40,445	D
Ordinary Shares	06/02/2026		S		1,481	D	$209.51⁽¹⁾	38,964	D
Ordinary Shares								27,242	I	See Footnotes Below⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$71.4	06/02/2026		M			3,781	⁽⁴⁾	08/10/2026	Ordinary Shares	3,781	$0	0	D

Explanation of Responses:

1. Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

2. Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").

3. Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.

4. This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.

Remarks:

	/s/ John P. Ubbing, Authorized Representative under Power of Attorney	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Richard C. Breeden report for STERIS (STE)?

Richard C. Breeden reported exercising options for 3,781 STERIS Ordinary Shares at $71.40 and selling 1,481 shares at a weighted average price of $209.51 on June 2, 2026. The filing also updates his direct and indirect share ownership totals.

How many STERIS (STE) shares did Richard C. Breeden sell and at what price?

He sold 1,481 STERIS Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share. Footnotes state this average reflects multiple trades between $209.50 and $209.53, with full trade details available on request from stakeholders.

What stock options did Richard C. Breeden exercise in the latest STERIS (STE) Form 4?

Breeden exercised an Employee Stock Option for 3,781 STERIS Ordinary Shares at a conversion or exercise price of $71.40 per share. The option, covering exactly 3,781 shares, became fully exercised, leaving zero remaining option shares after the June 2, 2026 transaction.

How many STERIS (STE) shares does Richard C. Breeden own after these transactions?

After the reported transactions, Breeden directly owned 38,964 STERIS Ordinary Shares. The filing also lists 27,242 shares held indirectly through affiliated investment entities, where he may be deemed an indirect beneficial owner under SEC rules, subject to a stated beneficial ownership disclaimer.

How are Richard C. Breeden’s indirect STERIS (STE) holdings structured?

Indirect holdings of 27,242 STERIS Ordinary Shares are attributed to Breeden Partners L.P. and its general partner Breeden Capital Partners LLC, managed by Breeden. Footnotes explain he may be deemed an indirect beneficial owner under Rule 16a-1(a)(2)(ii)(B), while disclaiming beneficial ownership of 1,358 of these shares.